)
Edge1 May 2026
Making the Marlboro Man
The story of Marlboro's transformation from a women's cigarette to a global icon: one of the most effective brand repositionings in history.
Racura Oncology
Racura Oncology (RAC) investor relations material
Racura Oncology Q3 2026 TU earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 TU earnings summary29 Apr, 2026
Executive summary
Developed a new blood-based molecular test to evaluate cardioprotective effects of RC220 in the CPACS Phase 1 trial.
Initiated collaboration with Emory University to study (E,E)-bisantrene in osimertinib-resistant EGFRm NSCLC models.
First patient recruited to Phase 1 HARNESS-1 clinical trial for NSCLC with EGFR mutations.
Presented findings on (E,E)-bisantrene's MYC gene silencing at AACR 2026 Annual Meeting.
Held inaugural R&D Symposium, outlining clinical programs and commercial strategy.
Financial highlights
Cash and cash equivalents at 31 March 2026 totaled $19.38 million.
81% of quarterly spending ($2.44m) directed to R&D and drug manufacturing.
Net cash used in operating activities for the quarter was $(3.01)m; for nine months, $(5.20)m.
Early conversion of options provided $1.44m in additional funding.
Estimated 6.45 quarters of funding available at current burn rate.
Outlook and guidance
Current cash position expected to fund all committed activities through calendar year 2027.
Ongoing focus on advancing clinical trials and exploring partnerships or M&A to accelerate RC220 access.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Racura Oncology
- RC220 clinical milestones, narrowed net loss, and strengthened leadership drive future growth.RAC
H2 20252 Apr 2026 - Advanced RC220 bisantrene to clinical trial readiness with robust financial and operational progress.RACH2 202427 Mar 2026
- Discovery of a novel anticancer mechanism and strong funding support major clinical expansions.RACQ2 2026 TU28 Jan 2026
- Significant clinical and strategic progress, board renewal, and focus on anti-aging research.RACAGM 202412 Jan 2026
- Breakthrough IP, strong cash, and global trial progress position for growth through CY2026.RACQ1 2026 TU30 Oct 2025
- (E,E)-bisantrene targets G-quadruplexes, downregulates MYC, and enables precision oncology.RACStatus Update8 Oct 2025
- EE bisantrene patent filings secure long-term exclusivity and open major commercial opportunities.RACStatus Update18 Sep 2025
- First patient dosed in RC220 Phase 1 trial; $13.67m cash supports operations into 2026.RACQ4 2025 TU22 Jul 2025
- RC220 aims to deliver safer, more effective cancer treatment with strong market potential.RACInvestor Presentation1 Jul 2025
Next Racura Oncology earnings date
Q4 202621 Jul, 2026
Racura Oncology
Next Racura Oncology earnings date
Q4 202621 Jul, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage